comparemela.com

Latest Breaking News On - Rs biotherapeutics - Page 1 : comparemela.com

RS BioTherapeutics Promotes Michelle L Shuffett, MD to

RS BioTherapeutics is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer. .

United statesDavid gutierrezMichellel shuffettDean hartLos angelesTherapeutic expert councilResearch collaboration agreementBoehringer ingelheimEveryday healthDresner corporate servicesLondon school of economicsMillion ways foundationSea sprite international ltdUniversity of kentuckySynapse medical communicationsScientific affairs

RS BioTherapeutics Appoints Michelle L Shuffett, MD as SVP

CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research,.

Michellel shuffettDavid gutierrezLos angelesDean hartSea sprite international ltdDresner corporate servicesSynapse medical communicationsUniversity of kentuckyLondon school of economicsScientific affairsMillion ways foundationEveryday healthBoehringer ingelheimSenior vice presidentHospital losLondon school

RS BioTherapeutics Appoints Pharmaceutical Industry Veteran

CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the.

Dean hartJustin molignoniDavid gutierrezDresner corporate servicesMaster of business administrationKelly school of business at indiana universityTakeda pharmaceuticals north americaEisai incKellogg school of management at northwestern universityChief executiveCommex consultingChief strategy officerKellogg schoolNorthwestern universityBusiness managementOkelly school

RS BioTherapeutics Selects Recipharm as Product

Takes important step towards filing an IND for RSBT-001 in the treatment of COPD.

United kingdomJustin molignoniChris hirstContract developmentReal science holdcoMarshall universityManufacturing organizationInvestigational new drugChief strategy officerManufacturing organizationsAdvanced delivery systems business unitCystic fibrosisAcute respiratory distressEndocannabinoid systemRs biotherapeutics

RS BioTherapeutics Secures $3 Million Seed II Round of

CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the.

United statesJustin molignoniReal science holdcoMarshall universityCystic fibrosisAcute respiratory distressChief strategy officerEndocannabinoid systemRs biotherapeutics

vimarsana © 2020. All Rights Reserved.